Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2008

BD Invests $4.5M in U.S. Genomics and Enters Diagnostic Partnership

  • BD (Becton, Dickinson and Company) made a $4.5 million equity investment in U.S. Genomics and entered into a collaboration to develop an infectious disease diagnostic platform.

    The partnership will leverage U.S. Genomics' DirectLinear Analysis (DLA) technology for the detection of infectious organisms in a single test.

    U.S. Genomics reports that it has invested in excess of $50 million in DLA technology, which integrates labeling strategies, advanced microfluidics, and optical engineering. It enables the identification of pathogens by analyzing individual DNA molecules present in a clinical sample.

    DLA has the potential to provide information such as which drugs a specific pathogen may be resistant to and which drugs could be used for most effective patient treatment, according to the companies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »